摘要
目的:探讨无创双水平正压通气(BiPAP)联合尼可刹米对慢性阻塞性肺疾病(COPD)合并肺性脑病患者血气指标及炎症因子水平的影响。方法:选取COPD并肺性脑病患者88例,用随机数表法分为两组,每组各44例,对照组采用BiPAP辅助治疗,观察组采用BiPAP联合尼可刹米治疗。对比两组血气指标及炎症因子水平。结果:治疗后,观察组PaCO2水平较低,PaO2水平较高;IL-6、IL-8、IL-10水平较低,与对照组比较差异有统计学意义(P<0.05)。结论:BiPAP联合尼可刹米治疗COPD合并肺性脑病,可增强患者通气,改善血气指标,降低炎症,缓解脑损伤。
objective:To explore the influence of blood gas index and inflammatory factor levels treated by Noninvasive bi-level positive pressure ventilation(BiPAP)combined with Nikethamide in patients of chronic obstructive pulmonary disease(COPD)complicated with pulmonary encephalopathy.Methods:88 cases of COPD complicated with pulmonary encephalopathy were selected and divided into two groups with the stochastic mathematical table law,44 cases in each group.The control group was treated by BiPAP assistance treatment.The observation group was treated by BiPAP combined with Nikethamide.The blood gas index and inflammatory factor levels between the two groups were compared.Results:After the treatment,PaCO2 level was low,PaO2 target level was high,IL-6,IL-8,and IL-10 level in the observation group were low,as compared to the control group,with the statistics significant difference(P<0.05).Conclusion:BiPAP combined with Nikethamide to treat COPD complicated with pulmonary encephalopathy may strengthen the ventilation of patient,improve the blood gas index,reduces the inflammation,alleviates the brain damage.
作者
范韶林
FAN Shaolin(Department of Medicine,The People’s Hospital of Baofeng County,Baofeng 467400,China)
出处
《华夏医学》
CAS
2020年第1期60-63,共4页
Acta Medicinae Sinica
